[The effect of collagenase inhibition on bullous eruption and healing process in epidermolysis bullosa].
The collagenase inhibiting effect of erythromycin already observed in vitro was demonstrated also after oral administration of the drug in vivo in one child with epidermolysis bullosa letalis and one child with epidermolysis bullosa dystrophica. Despite inhibition of skin collagenase activity during administration of the drug the frequency of bullous eruptions and healing process of affected skin areas remained unchanged. This suggests no direct causal relation existing between skin collagenase activity and epidermolysis bullosa. Whether increased collagenase activity reflects a secondary reaction of the organism cannot be concluded from this study.
D002648:Child; D004820:Epidermolysis Bullosa / Q000188:drug therapy* / Q000201:enzymology; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D003012:Microbial Collagenase / Q000037:antagonists & inhibitors* / Q000378:metabolism
D004917:Erythromycin; D003012:Microbial Collagenase
Einfluss von Kollagenasehemmung auf Blasenbildung und Heilungsverlauf bei Epidermolysis bullosa.